---
figid: PMC4450766__MOL2-8-1339-g005
figlink: /pmc/articles/PMC4450766/figure/mol22014871339-fig-0005/
number: Figure 5
caption: The EGFR pathway and the model of the effect of EGFR/MEK/EGFR + MEK inhibition
  on the pathway in RAS‐active NSCLC cell lines. EGFR monotherapy inhibits activation
  of EGFR, KRAS and AKT (blue), while U0126 inhibits the activity of MEK, preventing
  the activation of ERK (red). Combined therapy leads to the inhibition of all the
  aforementioned proteins (blue and red) plus RPS6 and RAF1 (purple), which are also
  degraded.
pmcid: PMC4450766
papertitle: Genomic classification of the RAS network identifies a personalized treatment
  strategy for lung cancer.
reftext: Nader N. El-Chaar, et al. Mol Oncol. 2014 Oct;8(7):1339-1354.
pmc_ranked_result_index: '110502'
pathway_score: 0.9185998
filename: MOL2-8-1339-g005.jpg
figtitle: EGFR pathway and the model of the effect of EGFR/MEK/EGFR + MEK inhibition
  on the pathway in RAS‐active NSCLC cell lines
year: '2014'
organisms: Homo sapiens
ndex: 1bbd01e7-df0a-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4450766__MOL2-8-1339-g005.html
  '@type': Dataset
  description: The EGFR pathway and the model of the effect of EGFR/MEK/EGFR + MEK
    inhibition on the pathway in RAS‐active NSCLC cell lines. EGFR monotherapy inhibits
    activation of EGFR, KRAS and AKT (blue), while U0126 inhibits the activity of
    MEK, preventing the activation of ERK (red). Combined therapy leads to the inhibition
    of all the aforementioned proteins (blue and red) plus RPS6 and RAF1 (purple),
    which are also degraded.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - AKT3
  - AKT2
  - MAP2K2
  - RAF1
  - EGFR
  - SOS2
  - MAP2K1
  - MAPK1
  - RPS6
  - KRAS
  - SOS1
  - MAPK3
  - U0126
  - Cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: RAF1
  symbol: RAF1
  source: hgnc_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RPS6
  symbol: RPS6
  source: hgnc_symbol
  hgnc_symbol: RPS6
  entrez: '6194'
- word: KRAS-GDP
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
chemicals:
- word: U0126
  source: MESH
  identifier: C113580
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
